Wanbury Launches Key API Products in FY27, Targeting ₹100 Crore Revenue
Wanbury Limited announced the launch of key API products at its Tanuku facility, targeting ₹100 crore plus incremental revenue in FY 2026-27. The company is introducing four high-value APIs: Antidiabetic, Anticoagulant, Antidepressant, and Anti Tussive molecules. The Tanuku facility is expected to be ready by March 2026.
The launch of new API products and the targeting of significant revenue growth (₹100 crore+) indicates a material impact on the company's future financial performance and market presence.
The announcement details the launch of new products and expansion of manufacturing capabilities, which are positive developments for the company's revenue growth and market position.
Wanbury Limited has announced the commercial launch of key API products at its state-of-the-art Tanuku facility in Andhra Pradesh. This initiative is set to commence in FY 2026-27 and aims to generate incremental revenues of approximately ₹100 crore plus additional revenue from new products in FY 2026-27.
The company is launching four high-value APIs: Antidiabetic, Anticoagulant, Antidepressant, and Anti Tussive molecules. This expansion is projected to deliver over ₹100 crore in revenue for FY 2025-26 and substantial growth opportunities globally. The Tanuku facility is on track for commercial readiness by the end of March 2026 and will enable the production of four additional high-value APIs in its pipeline.
Mr. Mohan Raayana, Director of Wanbury Limited, expressed excitement about the strategic expansion, stating, "We are excited about this strategic expansion, which strengthens our API portfolio and our commitment to meeting global healthcare needs with reliable, high-quality API." The company's robust API portfolio includes Metformin, Sertraline, Tramadol, and various other products in the pipeline, serving therapeutic categories like gastrointestinal, anti-inflammatory, and analgesics.
What to do with a filing like this
Wanbury Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Wanbury Limited. Read the original for the full detail.